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Background: CD133-positive liver cancer stem cells, which are characterized by their resistance to conventional
chemotherapy and their tumor initiation ability at limited dilutions, have been recognized as a critical target in liver
cancer therapeutics. In the current work, we developed a label-free quantitative method to investigate the
proteome of CD133-positive liver cancer stem cells for the purpose of identifying unique biomarkers that can be
utilized for targeting liver cancer stem cells. Label-free quantitation was performed in combination with ID-based
Elution time Alignment by Linear regression Quantitation (IDEAL-Q) and MaxQuant.
Results: Initially, IDEAL-Q analysis revealed that 151 proteins were differentially expressed in the CD133-positive
hepatoma cells when compared with CD133-negative cells. We then analyzed these 151 differentially expressed
proteins by MaxQuant software and identified 10 significantly up-regulated proteins. The results were further
validated by RT-PCR, western blot, flow cytometry or immunofluorescent staining which revealed that prominin-1,
annexin A1, annexin A3, transgelin, creatine kinase B, vimentin, and EpCAM were indeed highly expressed in the
CD133-positive hepatoma cells.
Conclusions: These findings confirmed that mass spectrometry-based label-free quantitative proteomics can be
used to gain insights into liver cancer stem cells.
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Numerous studies have identified a subpopulation of
cells in a wide variety of tumors that possess stem cell
characteristics, including the ability to self-renew and
differentiate into heterogeneous tumor cells [1,2].
These cells are called “cancer stem cells” (CSCs) or
“tumor-initiating cells” (TICs) [3]. CSCs were first dis-
covered in leukemia [4,5] and were subsequently identi-
fied in various solid tumors, including melanoma [6],
breast cancer [7], brain tumors [8,9], prostate cancer
[10], head and neck cancer [11], lung cancer [12], colon
cancer [13,14], pancreatic adenocarcinoma [15], ovar-
ian cancer [16], and hepatocellular carcinoma (HCC)
[17,18]. There is accumulating evidence that CSCs dis-
play drug resistance to many conventional therapies* Correspondence: cnshen@gate.sinica.edu.tw; winschen@gate.sinica.edu.tw
1Institute of Biochemistry & Molecular Biology, National Yang-Ming University,
Taipei, Taiwan
2Genomics Research Center, Academia Sinica, Taipei, Taiwan
Full list of author information is available at the end of the article
© 2012 Tsai et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwhich therefore leads to cancer recurrence, suggesting
that new cancer therapeutics may be required to target
and eliminate the cancer stem cells. Therefore, a better
understanding of the mechanisms that control the
aspects of self-renewal and survival in cancer stem cells
is very important. Furthermore, the identification of
unique biomarkers could also facilitate the develop-
ment of therapeutics that target CSCs.
The CD133 antigen (prominin-1) is a cell-surface
glycoprotein that contains 865 amino acids, 5 trans-
membrane domains, and 2 glycosylated extracellular
loops [19]. The glycosylated CD133 antigen that is
recognized by AC133 monoclonal antibodies is a cell
surface marker of hematopoietic stem cells and possibly
hepatic stem cells [20,21]. Recent findings have also
revealed that the glycosylated CD133 antigen is also a
potential marker for the isolation of CSCs from a wide
variety of tumor tissues, including glioblastomas, lung
cancer, pancreatic adenocarcinomas, prostate cancer,
colon cancer and hepatocellular carcinomas [8,10,12-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Experimental scheme for the label-free quantitation
analysis of human hepatocytes, CD133+ Huh7 cells, and
CD133- Huh7 cells.
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http://www.proteomesci.com/content/10/1/6914,22-24]. Recent reports suggest a subpopulation of
liver cancer cells expressed the glycosylated CD133
antigen are with characteristics of CSCs and can lead
to cancer progression and relapse [17,23-25]. More import-
antly, CD133 is a prognostic marker that has either been
linked to poor survival for liver cancer patients [26] or has
been correlated with higher grade tumors [27]. Therefore,
CD133-positive liver cancer cells have been recognized as a
critical target for liver cancer therapies.
The mass spectrometry (MS)-based proteomics tech-
nology has been shown as a powerful tool for large-
scale protein identification and quantitation. To inves-
tigate the differentially expressed proteins in a complex
biological system, strategies for reproducible and accur-
ate quantification are required. Several quantitative
proteomics methods have been developed, including
stable isotope labeling and label-free methods [28]. Al-
though isotope labeling techniques have been widely
used in quantitative proteomics research, researchers
are increasingly turning to label-free shotgun proteo-
mics techniques. Although both methods have certain
strengths and weaknesses, MS-based label-free quanti-
tative proteomics may be adequate for application in
complex biological systems [29,30]. Over the past few
years, a limited number of groups have applied proteo-
mics to investigate CSCs. For example, Ma et al., and
Lee et al. had utilized two-dimension electrophoresis
(2-DE) to determine the differently expressed proteins
in CD133+ liver cancer cells and identified ALDH1A1
and transgelin were highly expressed in CD133+ cells
compared with CD133- cells [31,32]. Nevertheless, the
2-DE method is less efficient and time-consuming. Re-
cently, Van Houdt et al. applied LC-MS/MS in combin-
ation with spectral counting for label-free quantitation
to analyze colorectal cancer stem cells and identified
BIRC6 as a key mediator of drug resistance against cis-
platin and oxaliplatin [33]. However, label-free quantita-
tive proteomics encounters the problem of less accuracy
although the method is rather simpler and cheaper.
In order to improve accuracy of label-free quantita-
tive proteomics, in the current work, label-free quanti-
tation was performed in combination with ID-based
Elution time Alignment by Linear regression Quantita-
tion (IDEAL-Q) [34] and MaxQuant [35,36]. Subpopu-
lations of Huh7 hepatoma cells that did or did not
express the glycosylated CD133 antigen (prominin-1)
were sorted and analyzed by mass spectrometry-based
comparative proteomics. The protein abundance in
CD133+/− Huh7 hepatoma cells and normal human
hepatocytes was initially determined by averaging the
peptide abundances with IDEAL-Q which computed
the area of the extracted ion chromatogram (XIC) fol-
lowed with validation by MaxQuant. The experimental
design is shown in Figure 1. Using the approach, weestablished the proteomes of CD133+/− Huh7 hepatoma
cells and normal human hepatocytes and identified a
number of proteins that differentially expressed in the
CD133-positive hepatoma cells. The results showed
that the MS-based label-free quantitative proteomics
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gain further insights into liver CSCs.
Results
Characterization of the CD133-positive subpopulation of
the Huh7 hepatoma cells
Previous works have demonstrated that Huh7 hepa-
toma cells contain a CD133-positive subpopulation,
which displays the characteristics of cancer stem cells
[17,23,25]. We initially determined whether the Huh7
cells contained a subpopulation of CSCs that expressed
the CD133 antigen. The Huh7 cell lines were first
stained with fluorescence-conjugated primary anti-
bodies against the surface marker CD133 and then ana-
lyzed using flow cytometry. We categorized the 20% of
cells displaying the strongest fluorescence as CD133+
Huh7 cells and the 20% of cells displaying the weakest
fluorescence as CD133- Huh7 cells. A re-analysis was
performed, which showed that CD133+ cells and
CD133- cells were indeed two different populations of
cells (Figure 2A). Further characterization of the
CD133+ Huh7 cells by RT-PCR and immunofluores-
cent staining showed that these cells expressed higher
levels of prominin-1, β-catenin, and cytokeratin 19
(CK19) (Figure 2B-C), which confirmed previous find-
ings [17]. In order to determine whether CD133+ Huh7
cells expressed characteristics of CSCs, we performed
sphere-forming experiments, TopFlash assay and drug
resistance test. Indeed, sphere forming assay has been
widely used to examine anchorage-independent growth
ability of stem cells and CSCs in liver [37-39]. As
shown in Figure 2D-E, in comparing with CD133-
Huh7 cells, CD133+ Huh7 cells generated more
spheres. Moreover, Wnt/β-catenin pathway is known
to play a key role in the self-renewal of normal and
tumorigenic liver stem/progenitor cells [40,41], we
then examined if CD133+ cells have activated Wnt/β-
catenin pathways. Immunofluorescent staining was
performed and showed that some CD133+ cells had
nuclear β-catenin (Figure 2F). TopFlash reporter assay
was carried out and further confirmed that CD133+
subpopulations had higher Wnt/β-catenin pathway
activities compared with CD133- subpopulation or un-
sorted Huh7 cells (Figure 2G). Since CSCs are known
to display drug resistance to many conventional ther-
apies, we then examined the drug resistance of Huh7
cells against two conventional drugs, 5-fluoroucacil
(5-FU) and Sorafenib which are widely used in treating
HCC. The sensitivity of Huh7 cells was determined
using MTT colorimetric assay followed by FACS ana-
lysis. As shown in Figure 2H, Huh7 cells displayed re-
sistance to 5-FU or Sorafenib with higher IC50 value of
160 and 3 μM respectively. Most importantly, the
majority of survived cells from 5-FU or Sorafenibtreatment were CD133+ (Figure 2I) suggesting CD133+
Huh7 cells display higher drug resistance.
Determination of the proteomes of the CD133+ and
CD133- subpopulations of Huh7 cells and normal
hepatocytes
To identify the differentially expressed proteins in
CD133+ liver cancer stem cells, we determined the pro-
teomes of human hepatocytes and the CD133+ and
CD133- subpopulations of the Huh7 cells. All protein
extracts, isolated from either the hepatocytes or the
CD133+ and CD133- subpopulations, were analyzed
twice using LC LTQ-FT-ICR. We identified 13,643,
17,707, and 21,865 non-redundant peptides from extracts
of the human hepatocytes, CD133+, and CD133- Huh7
subpopulations, respectively. Additionally, 1,869, 2,936,
and 3,009 proteins were identified from extracts of the
human hepatocytes, CD133+, and CD133- subpopula-
tions, respectively. Among the proteins identified, 1,471,
2,260, and 2,567 proteins, respectively, had more than 2
peptides that were detected. A comparison of the proteins
identified in the three cell types is shown in Figure 3A.
The detailed information on the complete proteomes of
the human hepatocytes, CD133+ Huh7 cells, and CD133-
Huh7 cells are included in Additional file 1: Table S1,
Additional file 2: Table S2 and Additional file 3: Table S3.
Identification of the significantly up-regulated and down-
regulated proteins in the CD133+ subpopulations of the
Huh7 cells
To identify proteins that were either significantly up-
regulated or down-regulated in the CD133+ subpopula-
tion, IDEAL-Q was used to calculate the ratios of the
protein abundance and to determine the significant dif-
ference (p<0.01) in the ratios of the protein abundance
between the CD133+ and CD133- subpopulations. The
distribution of the ratios of the protein abundance
between the CD133+ and CD133- subpopulations is
shown in Figure 3B. The data showed no significant dif-
ference in the level of most of the proteins, and a total
151 proteins were found to be differentially expressed in
the CD133+ subpopulations when compared with the
CD133- subpopulations. In order to select the specific
target proteins in the CD133+ subpopulations, the differ-
entially expressed proteins were also compared with
those in normal human hepatocytes and further analyzed
by MaxQuant [35]. Based on the IDEAL-Q and Max-
Quant analysis, we found 10 proteins that were abun-
dantly expressed in the CD133+ cell populations when
compared to the CD133- cell populations and the normal
human hepatocytes (Table 1). These proteins have been
quantified by using more than three unique peptides.
The difference in the expression level of these 10
proteins in CD133+, CD133- Huh7 cell populations, and
Figure 2 (See legend on next page.)
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Figure 2 Characterization of CD133+ Huh7 and CD133- Huh7 cells. (A) Re-analysis of FACS-sorted CD133+ and CD133- Huh7 cells. (B) RT-PCR
analysis of CD133+ and CD133- Huh7 cells. (C) Immunofluorescent staining of CD133+ and CD133- Huh7 cells with anti-β-catenin and anti-CK19
antibodies. (D) Formation the anchorage-independent spheres in stem cell medium. (E) Quantitative analysis of sphere-forming efficiency of
CD133+ and CD133- Huh7 cells. (F) Immunofluorescent staining of CD133+ and CD133- Huh7 cells with anti-β-catenin antibody. Arrowed cells
showed nuclear staining of β-catenin. (G) Huh7 cells were transfected with equal amounts of either Super8xTOPFlash reporter or
Super8xFOPFlash reporter constructs. After 48 hours, the TopFlash/FopFlash luciferase activity of CD133+ and CD133- Huh7 cells was measured.
Values shown are relative luminescence. (H) Huh7 cells were treated with different concentration of 5-fluoroucacil (5-FU) or Sorafenib for 48
hours. The cell survival was determined using MTT assay. (I) Huh7 cells were treated with 160 μM of 5-FU or 3 μM of Sorafenib for 48 hours. The
expression of CD133 in survived cells was analyzed by flow cytometry
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cant. Since, the subpopulations of the Huh7 cells were
sorted based on the expression of prominin-1 (CD133),
and the analytic data showed the amount of prominin-1
protein in the CD133+ Huh7 cells was approximately 15-
fold higher than that in the CD133- Huh7 cells and 76-
fold higher than that in the human hepatocytes; hence,
these results suggest that the quantitative analysis using
IDEAL-Q is reliable. As expected, several markers of
liver cancer stem cells or hepatic stem cells could also
been identified by IDEAL-Q and shown to be up-
regulated in the CD133+ subpopulations. For example,
transgelin, an actin-binding protein, has been proven to
be highly expressed in CD133+ Huh7 cells [31]. In our
study, the expression level of transgelin was 16-fold
higher in the CD133+ subpopulations than that in the
CD133- populations. Among the proteins that were sig-
nificantly up-regulated in the CD133+ subpopulations of
the Huh7 cells, we verified that the CD133+ Huh7 cells
expressed higher levels of annexin A1, annexin A3, pro-
minin-1, transgelin, creatine kinase B, vimentin, and
EpCAM (Figure 4A-D), using RT-PCR, western blot,
immunocytochemical analysis, and FACS analysis. The
level of epithelial cell adhesion molecule (EpCAM),
which has also been shown to be highly expressed in liver
cancer stem cells [42], was 2.6-fold higher in the CD133+Figure 3 Proteome analysis. (A) Comparison of the protein profiles of hu
number of identified proteins in human hepatocytes (red), CD133+ Huh7 c
diagram. The other colors represent the overlap regions. (B) The protein rasubpopulations compared with the CD133- subpopula-
tions. The expression level of EpCAM in CD133+ and
CD133- populations were also detected by flow cytome-
try (Figure 4D). Two other hepatic stem cell markers,
vimentin and cytokeratin 19, were 8-fold and 3.7-fold
higher, respectively, in the CD133+ subpopulations
when compared to the CD133- subpopulations. Since
it has been shown that Snail1-induced epithelial-to-
mesenchymal transition is accompanied by enhancement
in stem cell characteristics during liver carcinogenesis
[43], we also examined the level of mesenchymal markers
by western blot (Figure 4B). Although the level of E-
cadherin was not decreased in CD133+ Huh7 cells, how-
ever, in addition to vimentin, up-regulation of N-cadherin
was also observed. Taken together, these results suggest
that mass spectrometry-based label-free quantitative
proteomics developed in the current study can be used
to gain the insights into liver cancer stem cells.
In addition to the significantly up-regulated proteins,
we also found 60 proteins that were down-regulated in
the CD133+ subpopulations when compared to the
CD133- subpopulations. The detailed list of the up- and
down-regulated proteins is listed in Additional file 4:
Table S4. Furthermore, in order to investigate the protein
locations of the identified proteins, the Gene Ontology
cellular component (GOCC) terms were annotated forman hepatocytes, CD133+ Huh7 cells, and CD133- Huh7 cells. The
ells (blue), and CD133- Huh7 cells (yellow) are shown by a Venn
tio distribution of CD133+ Huh7 cells/CD133- Huh7 cells
Table 1 Significantly up-regulated proteins in the CD133+ Huh7 cells
Accession Protein description Score Unique
peptides
Hepatocyte
area
CD133-
Huh7 area
CD133+
Huh7 area
IDEAL-Q
CD133+ /CD133-
IDEAL-Q
CD133+ /Hepatocyte
P-value a MaxQuant
CD133+ /CD133-b
Plasma
membrane c
IPI00216138 Transgelin 552 10 0.21 ± 0.05 0.13 ± 0.06 2.11 ± 0.30 15.96 9.99 <0.001 33.94
IPI00012540 Prominin-1 (CD133) 170 4 0.01 ± 0.01 0.05 ± 0.01 0.69 ± 0.09 15.24 76.22 <0.001 124.06 O
IPI00418471 Vimentin 1726 30 0.38 ± 0.03 0.82 ± 0.06 6.77 ± 0.47 8.24 17.77 <0.001 21.51 O
IPI00218918 Annexin A1 303 5 0.02 ± 0.002 0.04 ± 0.01 0.33 ± 0.03 7.83 21.93 <0.001 101.44 O
IPI00186460 Collagen alpha-1(II) chain 227 4 0.01 ± 0.01 0.15 ± 0.05 0.94 ± 0.06 6.10 67.07 <0.001 11.95
IPI00024095 Annexin A3 919 15 0.15 ± 0.003 0.44 ± 0.07 2.69 ± 0.48 6.10 17.70 <0.001 17.13 O
IPI00329650 Nucleoporin NUP53 252 4 0.05 ± 0.02 0.28 ± 0.04 1.29 ± 0.13 4.71 26.41 <0.001 3.62 O
IPI00296215 Tumor-associated calcium signal
transducer 1 (EpCAM)
204 3 0.01 ± 0.004 0.12 ± 0.01 0.31 ± 0.02 2.56 27.73 0.010 6.17 O
IPI00386208 Gastric-associated
differentially-expressed
protein YA61P
224 4 0.01 ± 0.01 0.42 ± 0.04 0.97 ± 0.07 2.34 108.22 0.008 13.90
IPI00022977 Creatine kinase B-type 1181 19 0.86 ± 0.15 6.39 ± 0.58 13.50 ± 2.43 2.11 15.66 0.009 2.03
a Significance B based on log(2) transformed ratios and intensity between CD133+ Huh7 cells and CD133- Huh7 cells.
b The ratio was calculated by MaxQuant label-free quantification.
c Proteins possibly locate on plasma membrane from Gene Ontology Cellular Component (GOCC) database.
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Figure 4 Validation of significantly up-regulated proteins in CD133+ Huh7 and CD133- Huh7 cells. (A) RT-PCR, (B) western blot analysis,
(C) immunofluorescent staining, and (D) FACS analysis were performed to validate significantly up-regulated proteins in CD133+ and CD133-
Huh7 cells. GAPDH in the RT-PCR and β-actin in the western blot were used as loading controls
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proteins had higher expression levels in the CD133+
Huh7 cells than in the CD133- Huh7 cells, six of them
which has been listed in Table 1 had higher expression
levels (>10-fold) in the CD133+ Huh7 cells when com-
pared with the hepatocytes. We therefore proposed that
these up-regulated plasma membrane proteins can pos-
sibly be used as markers for the enriched isolation of liver
cancer stem cells.
Signaling molecules identified in the CD133+ Huh7 cells
Several signaling pathways have been found in liver can-
cer stem cells that are involved in self-renewal, survival
signaling, and drug resistance [25,42]. For example, acti-
vation of the Wnt/β-catenin pathway has been shown to
be associated with a wide variety of cancers [44] and it
plays a very important role in regulating the self-renewal
of various stem cells and liver progenitors [40]. To in-
vestigate the signaling pathway that governing the behav-
ior of liver cancer stem cells, the Kyoto Encyclopedia of
Genes and Genomes (KEGG) terms were annotated for
the identified proteins. As expected, 21 of the identifiedproteins were involved in the Wnt/β-catenin pathway. In
addition to Wnt/β-catenin pathway, 41 proteins involved
in the MAPK pathway, and 6 proteins involved in the
Notch signaling pathway have also been identified (Figure 5).
The results implied both MAPK and Notch signaling
pathways would also be critical for regulating the tumori-
genic behavior of liver CD133+ CSC subpopulations.
To investigate the protein-protein interactions, the
proteins were mapped with the Search Tool for the Re-
trieval of Interacting Genes/Proteins (STRING) database
version 9. STRING is constructed based on both physical
and functional interactions. The differentially expressed
151 proteins were analyzed by STRING. To avoid spuri-
ous interactions in our large data set, we fetched all inter-
actions that had a confidence score of ≧0.7 (high
confidence). Several interaction groups were immediately
apparent and these interaction groups were labeled or-
ange circles (Figure 6). Prominin-1 was correlated with
CK-19, nestin, and EpCAM. These proteins were also
found to interact with vimentin. Vimentin is a type III
intermediate filament (IF) protein that is expressed in
liver stem cells. We also found groups of interaction
Figure 5 (See legend on next page.)
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Figure 5 Pathway analysis. Proteins involved in (A) Wnt/β-catenin pathway, (B) MAPK pathway, and (C) Notch pathway. The identified proteins
were up-regulated (red), down-regulated (green), or showed no significant change (yellow) in CD133+ Huh7 cells
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chrome c, glutathione, RNA splicing, and actin
polymerization.
Discussion
In the current study, we not only identified the pro-
teomes of human hepatocytes and CD133+/− Huh7 cells,
but we also quantified the abundance of each protein and
presented them in parts per million (ppm), which was
then used to determine the protein concentration and to
classify the individual protein as either a major or minor
component. In addition, the protein ratio was used toFigure 6 String database mapping reveals the interaction groups of tdetermine the relative abundance in the CD133+/− sub-
population. We found that there were 2,590 proteins
(77%) detected in both the CD133+ and CD133- Huh7
cells, but only 1,251 proteins (32%) were detected in
all three cell types, suggesting the CD133+ cells and
CD133- Huh7 cells have similar characteristics. Some
of the calculated protein ratios were found to be dif-
ferent between the IDEA-Q results and the MaxQuant
results. Both IDEA-Q and MaxQuant utilized the peptide
intensity, retention time and mass to charge, but IDEAL-
Q calculated the top three most abundant peptides and
determined the protein ratio by dividing the averagehe significantly regulated proteins.
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protein ratios as the median of all the ratios for the com-
mon peptides. The same method was also applied on a
second liver cancer cell line, PLC/PRF/5 that expressed
the hepatitis B surface antigen (HBsAg). We confirmed
that annexin A1, annexin A3, creatine kinase B, and
transgelin were also up-regulated in CD133+ PLC/PRF/5
cells. The proteomics results of PLC/PRF/5 cells are
listed in Additional file 5: Table S5). We presume that
this difference could be due to heterogeneity and the dif-
ferent causes of liver cancer. The identified proteins were
searched against the GOCC, and we classified 409 IDs as
plasma membrane proteins, including hepatic stem cell
markers (CD133, CK19, EpCAM, and vimentin). These
up-regulated plasma membrane proteins can be used as
new surface targets to enrich or investigate liver CSCs.
Interestingly, annexin A1 and annexin A3 were both up-
regulated in the CD133+ Huh7 cells (7.8- and 6.1-fold,
respectively). We found that annexin A2 was also slightly
up-regulated (1.9-fold). These three proteins all belong
to the same subgroup of the annexin family. Annexin A1
binds acidic phospholipids with a high affinity in the
presence of calcium ions. It is also an endogenous anti-
inflammatory protein that has roles in many diverse
cellular functions, such as membrane aggregation, in-
flammation, phagocytosis, proliferation, and apoptosis
[45]. In a previous study, primary hepatocytes isolated
from normal mice did not express annexin A1, but it was
strongly expressed in the liver cells of transgenic mice
during the development of hepatocarcinomas. Annexin
A1 can be expressed by stimulating epidermal growth
factor (EGF) or hepatic growth factor (HGF) [46]. In
addition, the up-regulation of annexin A1 in hepatic car-
cinogenesis has been correlated with the activation of the
EGF pathway [47]. In this study, we also observed more
protein expression of EGF in the CD133+ Huh7 cells.
Therefore, annexin A1 could be a potential marker for
targeting liver CSCs. Annexin A3 had an approximately
six-fold higher expression level in the CD133+ Huh7 cells
compared with the CD133- Huh7 cells. The role of
annexin A3 in cancer is still not fully understood, how-
ever, some proteomic studies have shown that annexin
A3 is a biomarker in lung adenocarcinomas [48], and an
overexpression of annexin A3 was detected in platinum-
resistant human ovarian cancer cells [49,50]. In the
human prostate cancer xenograft model, annexin A3 was
up-regulated and drug-resistant both in vivo and in the
xenograft [51]. In a previous study, annexin A3 was acti-
vated by a hepatocyte growth factor pathway and played
an important role in rat liver regeneration [52]. This im-
plies that annexin A3 may be activated by a hepatocyte
growth factor in the CD133+ Huh7 cells and is involved
in liver tumor growth. In this study, EpCAM was highly
expressed in the CD133+ Huh7 cells, and it was found tointeract with CD133. EpCAM is a biomarker for hepatic
stem cells, and it is also expressed in embryonic stem
cells [53-56]. In 2009, EpCAM+ HCC cells were identi-
fied as possible liver cancer stem cells, and the expression
of EpCAM is regulated by Wnt/β-catenin signaling [42].
Currently, several antibody-based therapeutic approaches
targeting EpCAM are being developed [57,58]. These
reports suggest that EpCAM is not only a biomarker of
liver cancer stem cells but also may be a therapeutic tar-
get. Metastasis is the main cause of lethality in cancer
patients. Cancer stem cells are responsible for both
tumor invasion and metastasis [7,18]. In the metastasis
process, epithelial-mesenchymal transition (EMT) is a
transient and reversible switch from an epithelial to a
mesenchymal cellular phenotype, to become highly mo-
tile and invasive. EMT is regulated by the Wnt/β-catenin,
TGFβ, and Notch pathways. In this study, we found sev-
eral proteins that are involved in EMT and that were also
up-regulated in the CD133+ Huh7 cells, such as transge-
lin, vimentin and collagen. Transgelin is a target of TGFβ
signaling that regulates migration and invasion [59]. In
addition, it is also co-expressed with several EMT-
associated genes, including N-cadherin, vimentin, Snail,
and Twist [31]. Vimentin is a mesenchymal marker that
was also up-regulated in the CD133+ Huh7 cells.
Vimentin was also found to be over-expressed in the
HCC tissues, and it is involved in the metastasis of HCC
[60]. In addition, vimentin has been found to be
expressed in multipotent progenitor cells from human
fetal livers [53]. Therefore, we identified higher levels of
vimentin in CD133+ Huh7 cells, which may imply that
the expression of vimentin is an important characteris-
tic of liver CSCs. Translationally controlled tumor pro-
tein (TCTP) is a highly conserved, hydrophilic nuclear
protein. TCTP is involved in many cellular processes
[61,62]. For example, TCTP interacts with BCL-XL to
protect cells against apoptosis [63,64]. More import-
antly, a recent report has shown that TCTP is a tran-
scription factor that regulates the pluripotent gene oct4
[65], which is the key factor in regulating the pluripo-
tency of embryonic stem cells. Thus, the higher levels of
TCTP identified in the CD133+ Huh7 cells may imply
that TCTP plays a role in regulating the stemness prop-
erties of liver CSCs.Conclusions
With the assistance of the label-free quantitation analysis
tool IDEAL-Q and MaxQuant, the current work identi-
fied several candidate proteins of liver cancer stem cells,
which can possibly be used in the future for targeting
liver cancer stem cells. Moreover, the proteome analysis
utilized in the present work has provided a comprehen-
sive characterization of CD133+ liver cancer stem cells,
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believe the proteome established in the current work can
aid in the understanding of the molecular basis of the
tumorigenic liver CSC subpopulations.
Methods
Cell culture
The hepatoma cell lines Huh7 and PLC/PRF/5 [66] were
maintained in Dulbecco’s modified Eagle’s medium
(Hyclone, South Logan, UT, USA) supplemented with
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA,
USA), 100 units/ml of penicillin, and 100 μg/ml of
streptomycin (Invitrogen) at 37°C in a humidified atmos-
phere containing 5% CO2. Human hepatocytes, pur-
chased from PromoCell, were maintained in Hepatocyte
Growth Medium (PromoCell, HD, GRE) at 37°C in a
humidified atmosphere containing 5% CO2.
Fluorescence-activated cell sorting
To isolate the CD133+ and CD133- fractions, Huh7 cells
were re-suspended in Hank’s balanced saline solution
(HBSS; Invitrogen) containing 2% FBS and 10 mM HEPES.
The cell density was adjusted to 1 × 107/ml, and the Huh7
cells were stained with phycoerythrin (PE)-conjugated anti-
human CD133 antibody (Miltenyi Biotec Inc., Cambridge,
MA, USA). After staining, the Huh7 cells were re-suspended
in HBSS containing 2% FBS and 1 mM HEPES and filtered
through a 40 μm mesh filter, and the CD133+ and CD133-
Huh7 fractions were sorted by a FACSAria™ (Becton Dickin-
son, San Jose, CA, USA).
Sphere forming assay
Freshly FACS-sorted CD133+ and CD133- Huh7 were
plated into ultra-low attachment 6-well plates (Costar,
Coining Inc) and cultured in DMEM/F12 medium sup-
plemented with 1X B27 supplement, 1% penicillin-
streptomycin, 0.4% bovine serum albumin, 200 ng/mL
epidermal growth factor (EGF), 10 ng/mL basic fibro-
blast growth factor (bFGF), 5 μg/mL insulin at 37°C in a
humidified atmosphere containing 5% CO2. Spheres
were formed after 24 hours. The number of spheres that
had diameter over 100 μM was count at Day 5.
RNA extraction and RT-PCR
To isolate the total RNA, 1 × 106 cells of both the
CD133+ and CD133- Huh7 cell fractions were collected
in microcentrifuge tubes containing 1 ml TRI ReagentW
(Applied Biosystems, Foster City, CA, USA). The RNA
was extracted according to the manufacturer’s protocol
and treated with RQ-1 DNase (Promega, Madison, WI,
USA) to remove contaminating genomic DNA. The pur-
ity and concentration of the RNA were determined with
a NanoDropW (NanoDrop Technologies, Wilmington,
DE, USA). First strand complementary DNA wassynthesized using SuperScript III reverse transcriptase
(Invitrogen). The PCR reactions were performed with
annealing temperatures of 57-58°C for either 23 or 35
cycles. The primer sequences used are listed in Additional
file 6: Table S6).
Immunofluorescence staining
The Huh7 cells were either cultured on non-coated glass
coverslips or cytospined onto slides at 250 × g for 5 min-
utes. The cells were fixed with 4% paraformaldehyde in
PBS for 30 minutes, permeabilized with 0.1% (v/v) Triton
X-100 in PBS for 30 minutes, and incubated in 2% block-
ing buffer (Roche, Indianapolis, IN, USA) before sequen-
tial incubation with the primary and secondary antibodies.
The antibodies were obtained as follows: mouse anti-
human β-catenin was obtained from Becton Dickinson,
rabbit anti-human α-fetoprotein was obtained from Dako,
mouse anti-cytokeratin 19 and mouse anti-vimentin were
purchased from Sigma, and the annexin A1 antibody was
purchased from Abnova (Taipei City, Taiwan).
Western blotting
The cell extracts were prepared by lysing unsorted,
CD133+, or CD133- Huh7 cells with RIPA buffer con-
taining 150 mM NaCl, 50 mM Tris–HCl (pH 8), 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, protease
inhibitors, and phosphatase inhibitors (Sigma). The cell
extracts were run on an 8-10% SDS-PAGE gel and trans-
ferred onto a Hybond-P membrane (GE Healthcare,
Buckinghamshire, NA, England), which was then probed
with the primary antibodies. The antibodies used in the
experiments are listed in Additional file 7: Table S7).
The signal was detected with an enhanced chemilumin-
escence kit (GE Healthcare).
TopFlash assay
TOPFlash reporter (containing seven TCF/LEF binding
sites) and FOPFlash reporter (containing six mutant
TCF/LEF binding sites which was used as a negative
control.) plasmids were originally obtained from
Addgene (Dr. Randall Moon). Huh7 cells plated in 6-
well plates at the density of 3 × 105 cells/well were
grown for 24 hours. Either TOPFlash or FOPFlash re-
porter plasmids (1 μg/well) was transfected together
with Renilla control luciferase plasmid (100 ng/well)
using Fugene HD (Roche) according to the manufacturer’s
instructions. 48 hours after transfection, Huh7 cells were
harvested and stained with PE conjugated anti-human
CD133 antibody. The CD133+ and CD133- Huh7 fractions
were sorted by a FACSAria. After sorting, CD133+ and
CD133- Huh7 cells were lysed, and then firefly and Renilla
luciferase activities were measured using the Dual-
Luciferase Reporter Assay System (Promega).
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Huh7 cells were seeded at the density of 7,500 cells/well
in 96-well plates and were treated with a serial dilution
of 5-FU or Sorafenib for 48 hours. The cytotoxicity of
the drug was determined using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltertrazolium bromide (MTT) colori-
metric assay (Sigma).
In-gel digestion
The cell lysates were separated on a 12% polyacrylamide
gel (10 × 10 cm, 0.75 mm thick), and the protein pat-
terns were observed by Coomassie blue staining. Each
lane was separated into 16 sections, and each section
was cut into 0.75 mm3 cubes. The gel pieces were de-
stained with a 25 mM NH4HCO3/50% acetonitrile
(ACN) solution. After reduction and alkylation reactions
using 10 mM DTT and 55 mM iodoacetamide, respect-
ively, the proteins were digested overnight with modified
trypsin (Promega, Madison, WI, USA) at 37°C. The
tryptic peptides were extracted with 1% trifluoroacetic
acid (TFA)/60% ACN. After lyophilization, the extracted
peptides were re-dissolved in a 0.1% TFA solution.
LC-MS/MS analysis
The mass analysis experiments were performed using a 7-
Tesla LTQ-FT-ICR (Linear quadrupole ion trap Fourier
transform ion cyclotron resonance) mass spectrometer
(Thermo Fisher Scientific, Waltham, MA, USA) equipped
with a nanoelectrospray ion source (New Objective Inc.,
Woburn, MA, USA), an Agilent 1100 Series binary high-
performance liquid chromatography pump (Agilent Tech-
nologies, Palo Alto, CA, USA), and a FAMOS autosampler
(LC Packings, San Francisco, CA, USA). The peptide mix-
tures were injected (5 μl) at a flow rate of 10 μl/min onto
a self-packed pre-column (150 μm I.D. × 15 mm, 5 μm,
100 Å). The chromatographic separation was performed
on a self-packed reversed phase C18 nano-column (75 μm
I.D. × 300 mm, 5 μm, 100 Å) at 300 nl/min with a 60 min
gradient of 0 to 32% acetonitrile in 0.1% formic acid. The
electrospray voltage was maintained at 2.5 kV, and the ca-
pillary temperature was set at 200°C. The full-scan MS
spectra (m/z 300–1800) were acquired with the FT-ICR
with a mass resolution of 100,000 at m/z 400. After the
completion of the full-scan survey, the 10 most abundant
ions detected in the full-MS scan were selected for peptide
sequence determinations using MS/MS experiments. Each
sample was analyzed in duplicate.
Protein identification
The peak-list files were obtained from the MS/MS data
using Extract_msn 4.0 software (Thermo), which included
the mass values and the intensity and charge of the pre-
cursor ions (parent ions with +2 or +3 charges in this
study). For protein identification, the MS/MS data weresubmitted to the International Protein Index (IPI) human
protein database (release 3.43, 72,340 sequences) using the
MASCOT 2.2.2 search engine (Matrix Science, Boston,
MA, USA) with the following settings: trypsin cleavage; a
peptide mass matching error tolerance of 5 ppm; a frag-
ment mass tolerance of 0.5 Da; fixed modification of car-
bamidomethylation of cysteine; variable modifications of
deamidation of asparagine and glutamine, oxidation of
methionine; a maximum of two missed cleavages; an ion
score cutoff of 33 (p < 0.003); and a false discovery rate
of < 1.1%. The false discovery rate was calculated by
decoy database searching. The results were imported
into Microsoft Excel for further analysis.
Quantitative data analysis
The IDEAL-Q method, which was developed previously
[34], was utilized to process the LC-MS/MS data, and the
Mascot search engine was used to extract the quantitative
information. In brief, the raw data files were first con-
verted into the mzXML data format by the ReAdW
program (http://tools.proteomecenter.org/wiki/index.php?
title=Software:ReAdW). The resulting mzXML files and
the Mascot search results for the peptide and protein
identification were used as the input for the quantitative
tool. To process a peptide of an LC-MS run, we extracted
the LC-MS data within the range of ± 1.5 minutes of its
elution time and ± 3.5 Da of the precursor m/z value for
quantitative analysis. We used the extracted ion chro-
matogram (XIC) to determine the peptide abundance in
an LC-MS run. After determining the peptide abundance
for each LC-MS run, we calculated the fraction’s peptide
abundance by averaging the peptide abundances of the
valid peptides in all of the LC-MS runs for the fraction. To
determine the peptide abundance in a sample, we summed
all of the peptide fraction abundances in the sample, and
the peptide ratio between two samples was also calculated.
To calculate the protein ratio, we selected the non-
degenerate peptides and performed the Dixon’s test to
eliminate the outliers for each protein. We then averaged
the abundances of the top three most abundant peptides,
and the protein ratio was determined by dividing the aver-
age value for each of the different cell types. The up-
regulated or down-regulated proteins were defined as
having a protein ratio with a significant change (p < 0.01).
Label-free quantitation was also performed in MaxQuant
[35,36] version 1.2.0.18. The significance B and p-values
were calculated by Perseus software.
Additional files
Additional file 1: Table S1. The information of identified proteins in
hepatocytes.
Additional file 2: Table S2. The information of identified proteins in
CD133+ Huh7 cells.
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